Insulin Aspart 30 — Competitive Intelligence Brief

Insulin Aspart 30 (Insulin Aspart 30) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin analog (rapid-acting/intermediate-acting combination). Area: Diabetes.

marketed Insulin analog (rapid-acting/intermediate-acting combination) Insulin receptor Diabetes Small molecule

Target snapshot

Insulin Aspart 30 (Insulin Aspart 30) — Medical University of Graz. Insulin Aspart 30 is a rapid-acting insulin analog that binds to insulin receptors on cells to facilitate glucose uptake and lower blood glucose levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Insulin Aspart 30 TARGET	Insulin Aspart 30	Medical University of Graz	marketed	Insulin analog (rapid-acting/intermediate-acting combination)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin analog (rapid-acting/intermediate-acting combination) class)

1. Medical University of Graz · 1 drug in this class